Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria (Q44164504)

30 November 2017

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria (English)

1 reference

30 November 2017

0 references

phase I clinical trial

0 references

0 references

1 reference

1 reference

13

1 reference

30 November 2017

David J Diemert

3

0 references

Jetsumon Sattabongkot

4

object named as

Jetsumon Sattabongkot

1 reference

30 November 2017

6

Kazutoyo Miura

1 reference

30 November 2017

7

Carole A Long

1 reference

30 November 2017

12

Louis H Miller

1 reference

30 November 2017

2

Anna P Durbin

1 reference

30 November 2017

1

Elissa M Malkin

1 reference

30 November 2017

8

Lynn Lambert

1 reference

30 November 2017

Yimin Wu

5

1 reference

30 November 2017

Aaron P Miles

9

1 reference

30 November 2017

Jin Wang

10

1 reference

30 November 2017

Anthony Stowers

11

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

30 November 2017

1 reference

30 November 2017

23

1 reference

30 November 2017

24

1 reference

30 November 2017

3131-3138

1 reference

Progress and challenges for malaria vaccines

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Current developments in malaria transmission-blocking vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Transmission blocking malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Interaction between host complement and mosquito-midgut-stage Plasmodium berghei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

The biosynthesis and post-translational modification of Pbs21 an ookinete-surface protein of Plasmodium berghei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Biosynthesis of the 25-kDa protein in the macrogametes/zygotes of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

Malaria transmission-blocking vaccines--how can their development be supported?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

The neglected burden of Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Murine complement reduces infectivity of Plasmodium yoelii to mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.12.019

1 reference

30 November 2017

1 reference